Reactogenicity and immunogenicity of Comirnaty
Conditions
Interventions
Group 1: timepoint 1 (6 months +- 4 weeks after second vaccination with Comirnaty): enrolment and blood sampling
anti-SARS-CoV-2 antibodies and neutralization activity.
timepoint 2 (not obligatory
4-8 weeks after a third vaccination with an mRNA vaccine): blood sampling
anti-SARS-CoV-2 antibodies and neutralization activity
survey on adverse reactions after third vaccination.
Sponsors
University Medical Center Regensburg
Eligibility
Sex/Gender
All
Age
21 Years to 66 Years
Inclusion criteria
Inclusion criteria: immunoreakt study participants who were included in the final analysis of the immunoreakt study
Exclusion criteria
Exclusion criteria: 1) new history of SARS-CoV-2 infection 2) new immunosuppression (disease or medication-induced)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) anti SARS-CoV-2 antibody course and neutralization activity 6 months (+- 4 weeks) after second vaccination with Comirnaty. 2) reactogenicity and immunogenicity of a third COVID-19 vaccination with an mRNA vaccine. | — |
Secondary
| Measure | Time frame |
|---|---|
| Persistence of an immunological benefit of men with severe adverse reactions after first and/or second vaccination with Comirnaty compared to men without adverse reactions after first and second vaccination. | — |
Countries
Germany
Contacts
Public ContactStilla Bauernfeind
University Medical Center Regensburg
Outcome results
None listed